CN111647035A - Preparation method of levonorgestrel - Google Patents

Preparation method of levonorgestrel Download PDF

Info

Publication number
CN111647035A
CN111647035A CN202010540656.8A CN202010540656A CN111647035A CN 111647035 A CN111647035 A CN 111647035A CN 202010540656 A CN202010540656 A CN 202010540656A CN 111647035 A CN111647035 A CN 111647035A
Authority
CN
China
Prior art keywords
organic solvent
levonorgestrel
reaction
potassium
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010540656.8A
Other languages
Chinese (zh)
Inventor
邵振平
王荣
王炳乾
王洪福
黄橙橙
雷灵芝
王友富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHEJIANG SHENZHOU PHARMACEUTICAL CO Ltd
Original Assignee
ZHEJIANG SHENZHOU PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHEJIANG SHENZHOU PHARMACEUTICAL CO Ltd filed Critical ZHEJIANG SHENZHOU PHARMACEUTICAL CO Ltd
Priority to CN202010540656.8A priority Critical patent/CN111647035A/en
Publication of CN111647035A publication Critical patent/CN111647035A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0088Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096Alkynyl derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention discloses a preparation method of levonorgestrel, belonging to the technical field of preparation and processing of medicines. The levonorgestrel is prepared by taking 18-methylestra-2, 5(10) -diene-3-methoxy-17-ketone as a starting material through the steps of ethynylation and hydrolysis. The preparation method of the levonorgestrel has the advantages of improving the defects of the traditional process, along with mild reaction conditions, high overall conversion rate, simple and convenient operation, suitability for industrial production and wide market prospect.

Description

Preparation method of levonorgestrel
Technical Field
The invention relates to the technical field of preparation of medicines, and particularly relates to a preparation method of levonorgestrel.
Background
The chemical name of the levonorgestrel is D (-) -17 alpha-ethynyl-17 beta-hydroxy-18-methylestra-4-en-3-one, and the levonorgestrel is an oral contraceptive with wider application. Levonorgestrel can inhibit ovulation and prevent pregnant ovum implantation, and simultaneously increases cervical mucus concentration and prevents sperm progression, thus being one of the most widely applied emergency contraceptives at home and abroad at present. Levonorgestrel can also be used for treating menoxenia, dysfunctional uterine bleeding and endometriosis.
The existing synthesis methods of levonorgestrel mainly comprise two methods:
the method is characterized in that DL-18-methyl-4-estrene-3, 17-diketone is used as a starting material, acetylene is introduced to react in the presence of potassium hydroxide, and the synthetic route of the 18-methylnorethindrone is as follows:
Figure BDA0002538706910000011
the method is characterized in that 18-methylestra-2, 5(10) -diene-3-methoxy-17-ketone is used as a starting material, potassium hydroxide is reacted with acetylene to prepare potassium acetylide, the potassium acetylide is subjected to ethynylation reaction with the starting material, and hydrolysis is carried out to obtain 18-methylnorethindrone, wherein the synthetic route is as follows:
Figure BDA0002538706910000021
in the two synthetic routes, water is generated in the reaction process, which is not beneficial to the proceeding of the ethynylation reaction, and the total conversion rate is not high, so that the method is not suitable for industrial production.
Disclosure of Invention
In order to solve the problems, the invention provides a preparation method of levonorgestrel, which has the advantages of simple reaction process, mild conditions and high conversion rate.
The purpose of the invention is realized by the following modes: a preparation method of levonorgestrel comprises the following steps:
Figure BDA0002538706910000022
the method specifically comprises the following steps:
1) alkynylation reaction: dissolving 18-methylestra-2, 5(10) -diene-3-methoxy-17-ketone (1) in an organic solvent A, adding an organic base A, controlling the temperature to be minus 20-30 ℃, introducing acetylene, stirring for reaction, adding an acid solution A for neutralization after the reaction is finished, concentrating, adding water for elutriation, and filtering to obtain an intermediate 2;
2) and (3) hydrolysis reaction: dissolving the intermediate (2) obtained in the step 1) in an organic solvent B, adding an acid solution B, reacting at-10-50 ℃, adding an alkali B for neutralization after the reaction is finished, concentrating, adding water for elutriation, filtering to obtain a crude product, refining the crude product with an organic solvent C, and drying to obtain the levonorgestrel.
Further, in the step 1), the organic solvent A is at least one of acetone, butanone, tetrahydrofuran, methyltetrahydrofuran, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide, toluene, xylene or sulfolane, and the volume amount of the organic solvent A is 5-30 times that of the substrate 18-methylestra-2, 5(10) -diene-3-methoxy-17-one (1); wherein the organic base A is one of potassium tert-butoxide, potassium isobutoxide, potassium isopropoxide, potassium ethoxide, sodium ethoxide or sodium methoxide, and the weight consumption of the organic base A is 1-5 times of that of 18-methylestra-2, 5(10) -diene-3-methoxy-17-ketone (1) serving as a substrate; wherein the acid solution A is one of aqueous solutions of hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid or formic acid, and the mass concentration of the acid solution A is 5-30%.
Further, the organic solvent B in the step 2) is one of acetone, butanone, tetrahydrofuran or methyl tetrahydrofuran, and the volume consumption of the organic solvent B is 5-30 times that of the substrate intermediate (2); wherein the acid solution B is a hydrochloric acid or sulfuric acid aqueous solution, the mass concentration of the acid solution B is 5-30%, and the dosage of the acid solution B is 0.5-5 times of that of the substrate intermediate (2); the alkali B is one of sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium sulfite, sodium hydroxide and potassium hydroxide aqueous solutions, and the mass concentration of the alkali B is 5-30%.
Further, the organic solvent C is one of methanol, ethanol and acetone.
Compared with the prior art, the invention has the beneficial effects that:
1. the reaction raw materials of the invention are cheap and easy to obtain.
2. The method has the advantages of short reaction route, low operation cost and simple and convenient operation, and is suitable for industrial production.
3. The method is carried out at low temperature or slightly higher than room temperature, the overall reaction is mild, the total mass yield is higher than 85%, and the product purity is higher than 99.0%.
4. In the traditional process, water is generated when potassium hydroxide is used for carrying out the alkynylation reaction, and the reaction is not carried out.
Detailed Description
The invention is further illustrated with reference to the following examples, which are not intended to limit the invention.
The specific experimental procedures or conditions are not shown in the examples, and the procedures can be performed according to the conventional experimental methods described in the publications in the field, and the reagents or equipment used are not indicated by manufacturers, and are all conventional products which can be obtained commercially.
Example 1 a method for the preparation of levonorgestrel, comprising the steps of:
1) alkynylation reaction: dissolving 18 g of methyl estra-2, 5(10) -diene-3-methoxy-17-ketone (1) in 750ml of tetrahydrofuran, adding 50g of potassium tert-butoxide, introducing acetylene at the controlled temperature of 5 ℃, stirring for reaction, adding a 5% hydrochloric acid aqueous solution for neutralization to neutrality after the reaction is finished, concentrating, adding water for elutriation, and filtering to obtain 52g of an intermediate 2;
2) and (3) hydrolysis reaction: dissolving 52g of the intermediate (2) obtained in the step 1) in 1500ml of acetone, adding 250ml of 5% hydrochloric acid aqueous solution, reacting at 0 ℃, adding 10% sodium carbonate aqueous solution to neutralize to be neutral after the reaction is finished, concentrating, adding water for elutriation, filtering to obtain a crude product, refining the crude product with methanol, and drying to obtain 43g of levonorgestrel, wherein the total mass yield of the product is 86% and the HPLC content is 99.3%.
Example 2 a method for preparing levonorgestrel, comprising the steps of:
1) alkynylation reaction: dissolving 18 g of methyl estra-2, 5(10) -diene-3-methoxy-17-ketone (1) in 250ml of dimethyl sulfoxide, adding 100g of potassium isopropoxide, controlling the temperature and introducing acetylene at 30 ℃, stirring for reaction, adding 10% sulfuric acid water solution A to neutralize to be neutral after the reaction is finished, concentrating, adding water for elutriation, and filtering to obtain 53g of intermediate 2;
2) and (3) hydrolysis reaction: dissolving 53g of the intermediate (2) obtained in the step 1) in 250ml of tetrahydrofuran, adding 27ml of 30% hydrochloric acid aqueous solution, reacting at-10 ℃, adding 5% sodium hydroxide aqueous solution to neutralize to be neutral after the reaction is finished, concentrating, adding water for elutriation, filtering to obtain a crude product, refining the crude product with ethanol, and drying to obtain 43.5g of levonorgestrel, wherein the total mass yield of the product is 87%, and the HPLC content is 99.2%.
Example 3 a method of preparing levonorgestrel, comprising the steps of:
1) alkynylation reaction: dissolving 18 g of methyl estra-2, 5(10) -diene-3-methoxy-17-ketone (1) in 1500ml of toluene, adding 250g of sodium ethoxide, controlling the temperature to be minus 20 ℃, introducing acetylene, stirring for reaction, adding 30% acetic acid aqueous solution for neutralization to be neutral after the reaction is finished, concentrating, adding water for water precipitation, and filtering to obtain 51g of an intermediate 2;
2) and (3) hydrolysis reaction: dissolving 51g of the intermediate (2) obtained in the step 1) in 750ml of butanone, adding 70ml of 10% sulfuric acid aqueous solution, reacting at 50 ℃, adding 30% sodium sulfite aqueous solution to neutralize to be neutral after the reaction is finished, concentrating, adding water for elutriation, filtering to obtain a crude product, refining the crude product with acetone, and drying to obtain 43g of levonorgestrel, wherein the total mass yield of the product is 86% and the HPLC content is 99.4%.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention.

Claims (3)

1. A preparation method of levonorgestrel is characterized by comprising the following preparation route:
Figure FDA0002538706900000011
the method specifically comprises the following steps:
1) alkynylation reaction: dissolving 18-methylestra-2, 5(10) -diene-3-methoxy-17-ketone (1) in an organic solvent A, adding an organic base A, controlling the temperature to be minus 20-30 ℃, introducing acetylene, stirring for reaction, adding an acid solution A for neutralization after the reaction is finished, concentrating, adding water for elutriation, and filtering to obtain an intermediate 2;
2) and (3) hydrolysis reaction: dissolving the intermediate (2) obtained in the step 1) in an organic solvent B, adding an acid solution B, reacting at-10-50 ℃, adding an alkali B for neutralization after the reaction is finished, concentrating, adding water for elutriation, filtering to obtain a crude product, refining the crude product with an organic solvent C, and drying to obtain the levonorgestrel.
2. The method for preparing levonorgestrel according to claim 1, wherein the organic solvent A in step 1) is at least one selected from acetone, butanone, tetrahydrofuran, methyltetrahydrofuran, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide, toluene, xylene and sulfolane, and the volume of the organic solvent A is 5-30 times that of the 18-methylestra-2, 5(10) -diene-3-methoxy-17-one (1) serving as a substrate; wherein the organic base A is one of potassium tert-butoxide, potassium isobutoxide, potassium isopropoxide, potassium ethoxide, sodium ethoxide or sodium methoxide, and the weight consumption of the organic base A is 1-5 times of that of 18-methylestra-2, 5(10) -diene-3-methoxy-17-ketone (1) serving as a substrate; wherein the acid solution A is one of aqueous solutions of hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid or formic acid, and the mass concentration of the acid solution A is 5-30%.
3. The method for preparing levonorgestrel according to claim 1, wherein the organic solvent B in the step 2) is one of acetone, butanone, tetrahydrofuran or methyltetrahydrofuran, and the volume of the organic solvent B is 5-30 times that of the substrate intermediate (2); wherein the acid solution B is a hydrochloric acid or sulfuric acid aqueous solution, the mass concentration of the acid solution B is 5-30%, and the dosage of the acid solution B is 0.5-5 times of that of the substrate intermediate (2); wherein the alkali B is one of sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium sulfite, sodium hydroxide and potassium hydroxide aqueous solutions, and the mass concentration of the alkali B is 5-30%; the organic solvent C is one of methanol, ethanol and acetone.
CN202010540656.8A 2020-06-15 2020-06-15 Preparation method of levonorgestrel Pending CN111647035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010540656.8A CN111647035A (en) 2020-06-15 2020-06-15 Preparation method of levonorgestrel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010540656.8A CN111647035A (en) 2020-06-15 2020-06-15 Preparation method of levonorgestrel

Publications (1)

Publication Number Publication Date
CN111647035A true CN111647035A (en) 2020-09-11

Family

ID=72345710

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010540656.8A Pending CN111647035A (en) 2020-06-15 2020-06-15 Preparation method of levonorgestrel

Country Status (1)

Country Link
CN (1) CN111647035A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114031659A (en) * 2021-11-22 2022-02-11 湖南科益新生物医药有限公司 Preparation method of levonorgestrel impurity O

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3418326A (en) * 1966-03-22 1968-12-24 American Home Prod 5-alkyl-13-polycarbon-gonanes
WO2012110947A1 (en) * 2011-02-17 2012-08-23 Lupin Limited An improved process for preparation of levonorgestrel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3418326A (en) * 1966-03-22 1968-12-24 American Home Prod 5-alkyl-13-polycarbon-gonanes
WO2012110947A1 (en) * 2011-02-17 2012-08-23 Lupin Limited An improved process for preparation of levonorgestrel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VON CLEMENS RUFER ET AL.: "Totalsynthese optisch aktiver Steroide, III Totalsynthese von optisch aktiven 13-Athyl-gonan-Derivaten", 《LIEBIGS ANN. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114031659A (en) * 2021-11-22 2022-02-11 湖南科益新生物医药有限公司 Preparation method of levonorgestrel impurity O

Similar Documents

Publication Publication Date Title
CN111606962B (en) Synthesis method of levonorgestrel
CN112062801B (en) Progesterone refining method
CN104262442A (en) Preparation method for progestin
CN105254512A (en) Preparation method of terbutaline sulphate
CN103664923B (en) The preparation method of Nifuratel
CN111647035A (en) Preparation method of levonorgestrel
CN110950920A (en) Preparation method of tetraeestrone
WO2021012671A1 (en) Highly efficient preparation method for progesterone with low pollution
CN104098640A (en) Progesterone preparation method
BRPI0814887B1 (en) process for toluidine compound production
CN114181272B (en) Synthesis method of levonorgestrel
CN114685593B (en) Fulvestrant preparation method and fulvestrant intermediate
CN115521231A (en) Environment-friendly clean preparation method of taurine
CN110483594B (en) Method for synthesizing azithromycin
CN111675745A (en) Preparation method of ethinylestradiol
CN108084238A (en) A kind of preparation method of canrenone intermediate
CN111470946B (en) Preparation method of 2-ethyl-1-butanol serving as midbody of Reidesciclovir
CN113416227A (en) Novel method for preparing medroxyprogesterone acetate
CN108623579B (en) Synthesis method of piroxicam
CN104311456A (en) Preparation method of guaiacol potassium sulfoacid
CN101955466A (en) Synthesis method of 5-trifluoromethyluracil
CN110054558A (en) A kind of preparation method of 1- trifluoromethyl cyclopropane -1- formic acid
CN112079894B (en) Preparation method of Levonorgestrel pharmacopoeia impurity V
CN101844989A (en) Preparation method for clofedanol and hydrochloride thereof
CN111995651A (en) Progesterone preparation method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200911

RJ01 Rejection of invention patent application after publication